Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 6/20 | 1.00 |
| ▸ | HTR2A | P28223 | 7/20 | 0.72 |
| ▸ | HTR2C | P28335 | 6/20 | 0.72 |
| ▸ | HTR1A | P08908 | 4/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | BCHE | P06276 | 1/20 | 0.65 |
| ▸ | HTR2B | P41595 | 3/20 | 0.60 |
| ▸ | HTR1B | P28222 | 2/20 | 0.60 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.60 |
| ▸ | HTR3B | O95264 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | DRD1 | P21728 | 1/20 | 0.60 |
| ▸ | HTR1E | P28566 | 1/20 | 0.60 |
| ▸ | HTR1F | P30939 | 1/20 | 0.60 |
| ▸ | HTR7 | P34969 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29355422 | 1.00 | HTR1D (1.00) | HTR1DHTR2AHTR2CHTR1ASLC6A4 | |
| SCHEMBL24243759 | 0.94 | HTR1D (0.90) | HTR1DHTR2AHTR2CHTR1ASLC6A4 | |
| SCHEMBL30276871 | 0.94 | HTR1D (0.90) | HTR1DHTR2AHTR2CHTR1ASLC6A4 | |
| SCHEMBL23069123 | 0.90 | HTR1D (1.00) | HTR1DHTR2AHTR2CHTR1ASLC6A4 | |
| SCHEMBL31244415 | 0.89 | HTR1D (0.79) | HTR1DHTR2AHTR2CHTR1ASLC6A4 | |
| SCHEMBL23069145 | 0.87 | HTR1D (0.78) | HTR1DHTR2AHTR2CHTR1ASLC6A4 | |
| SCHEMBL6986225 | 0.85 | HTR1D (0.73) | HTR1DHTR2AHTR2CHTR1ASLC6A4 | |
| SCHEMBL30183304 | 0.84 | HTR1D (0.72) | HTR1DHTR2AHTR2CHTR1ASLC6A4 | |
| Bufotenine SCHEMBL518028 | 0.84 | HTR2C (1.00) | HTR1DHTR2AHTR2CHTR1ASLC6A4 | |
| Bufotenine SCHEMBL29353068 | 0.84 | HTR2C (1.00) | HTR1DHTR2AHTR2CHTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595497-B2 | Processes for the production of tryptamines | COMPASS PATHFINDER LIMITED (GB) | 2026-04-07 | — | — | US | claimed |
| US-20220160737-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2022-05-26 | — | — | US | claimed |
| US-20260108544-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12595497-B2 | Processes for the production of tryptamines | COMPASS PATHFINDER LIMITED (GB) | 2026-04-07 | — | — | US | disclosed |
| US-20260048048-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20250325533-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12403150-B2 | Tryptamine compositions for enhancing neurite outgrowth | TURTLE BEAR HOLDINGS, LLC (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250205254-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2025-06-26 | — | — | US | disclosed |
| US-12257258-B2 | Tryptamine compositions for enhancing neurite outgrowth | TURTLE BEAR HOLDINGS, LLC (US) | 2025-03-25 | — | — | US | disclosed |
| US-12171771-B2 | Tryptamine compositions for enhancing neurite outgrowth | TURTLE BEAR HOLDINGS, LLC (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240335418-A1 | SAFER PSYCHOACTIVE COMPOSITIONS | ARCADIA MEDICINE, INC. | 2024-10-10 | — | — | US | disclosed |
| US-5594034-A | ADMINISTERING DIRECT ACTING 5-HYDROXYTRYPTAMINE AGONIST TO MAMMAL | ELI LILLY AND COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| US-5594025-A | Method of inhibiting gastric acid secretion with 5-substituted-3-aminochromane | ELI LILLY AND COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0455510-B1 | Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion | LILLY CO ELI (US) | 1996-11-27 | — | — | EP | disclosed |
| US-5576352-A | Method of inhibiting gastric acid secretion with aryloxypropanolamines | ELI LILLY AND COMPANY (US) | 1996-11-19 | — | — | US | disclosed |
| US-5457120-A | Antisecretory and antiserotonine agents | ELI LILLY AND COMPANY (US) | 1995-10-10 | — | — | US | disclosed |
| US-5340838-A | Administering serotonin agonist to mammals | ELI LILLY AND COMPANY (US) | 1994-08-23 | — | — | US | disclosed |
| US-5258379-A | ADMINISTERING IN AN EFFECTIVE DOSAGE TO MAMMALS | ELI LILLY AND COMPANY (US) | 1993-11-02 | — | — | US | disclosed |
| US-5158956-A | Administering serotonin receptor agonist | ELI LILLY AND COMPANY (US) | 1992-10-27 | — | — | US | disclosed |
| EP-0455510-A2 | Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion | ELI LILLY AND COMPANY (US) | 1991-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12403150-B2 | Tryptamine compositions for enhancing neurite outgrowth | HTR1B, HTR6, BDNF | HTR1D 15/4885HTR2A 11/4885HTR2C 6/4885 |
| US-12257258-B2 | Tryptamine compositions for enhancing neurite outgrowth | HTR1B, HTR6, BDNF | HTR1D 15/4885HTR2A 11/4885HTR2C 6/4885 |
| US-12595497-B2 | Processes for the production of tryptamines | INMT, TPH1, TPH2 | HTR1D 190/4885HTR2A 67/4885HTR2C 38/4885 |
| US-20260048048-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR1D 13/4885HTR2A 7/4885HTR2C 4/4885 |
| US-20220160737-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR1D 15/4885HTR2A 11/4885HTR2C 6/4885 |
| US-20250325533-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, BDNF, HTR6 | HTR1D 14/4885HTR2A 9/4885HTR2C 7/4885 |
| US-20240335418-A1 | SAFER PSYCHOACTIVE COMPOSITIONS | HTR6, HTR4, CNR1 | HTR1D 13/4885HTR2A 6/4885HTR2C 11/4885 |
| US-12171771-B2 | Tryptamine compositions for enhancing neurite outgrowth | HTR1B, HTR6, BDNF | HTR1D 15/4885HTR2A 11/4885HTR2C 6/4885 |
| US-20250205254-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR1D 15/4885HTR2A 11/4885HTR2C 6/4885 |
| US-20260108544-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR1D 7/4885HTR2A 9/4885HTR2C 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.